Albumin Market Share

North American Market Forecast

The albumin market in North America is projected to be the largest with a share of about 35% by the end of 2037. The growth of the market can be attributed majorly to the increasing production of immunoglobins and this is further driven by a rise in the number of HIV patients. Moreover, in 2021, Pfizer Inc. received the approval of the U.S. Food and Drug Administration (FDA) for the application of (sBLA) for PANZYGA, it is an intravenous immunoglobulin for treating the patient suffering from chronic inflammatory demyelinating polyneuropathy (CIDP).

APAC Market Forecast

The Asia Pacific albumin market is estimated to be the second largest, registering a share of about 28% by the end of 2037. The higher number of people suffering from heart issues will boost the market growth in the region. Albumin’s ability to exert oncotic pressure, which is important during cardiac surgery to prevent edema and ensure proper perfusion. Over the last several decades, projections of the overall incidence of coronary heart disease in India have dramatically increased from around 1.6% to nearly 7.4% in rural populations and from 1% to 13.2% in urban populations.